1
Tarran Jones
David M Hilbert, Tarran Jones, David G Williams: Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease. Medimmune, Aeres Biomedical, Jones Day, November 9, 2010: US07829086 (17 worldwide citation)

The present invention provides chimeric and humanized versions of anti-CD22 mouse monoclonal antibody, HB22.7. The anti-CD22 antibodies of the invention comprise four human or humanized framework regions of the immunoglobulin heavy chain variable region (“VH”) and four human or humanized framework r ...


2
Tarran Jones
Tarran Jones, David G Williams: Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease. MedImmune, Mueting Raasch & Gebhardt P A, March 4, 2014: US08664363

Provided herein are chimeric and humanized versions of anti-CD22 mouse monoclonal antibody, HB22.7, which comprise human or humanized framework regions of the immunoglobulin heavy chain variable region (“VH”) and light chain variable region (“VK”). The FW regions may contain one or more backmutation ...


3
Tarran Jones
Tarran Jones, David G Williams: Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease. Aeres Biomedical, Jones Day, March 5, 2013: US08389688

The present invention provides chimeric and humanized versions of anti-CD22 mouse monoclonal antibody, HB22.7. The anti-CD22 antibodies of the invention comprise four human or humanized framework regions of the immunoglobulin heavy chain variable region (“VH”) and four human or humanized framework r ...


4
Tarran Jones
David M Hilbert, Tarran Jones, David G Williams: Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease. Medimmune, July 28, 2011: US20110182887-A1

The present invention provides chimeric and humanized versions of anti-CD22 mouse monoclonal antibody, HB22.7. The anti-CD22 antibodies of the invention comprise four human or humanized framework regions of the immunoglobulin heavy chain variable region (“VH”) and four human or humanized framework r ...


5
Hilbert David, Jones Tarran, Williams David G: Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease. Medimmune, Aeres Biomedical, Hilbert David, Jones Tarran, Williams David G, CORUZZI Laura A, September 13, 2007: WO/2007/103470 (12 worldwide citation)

The present invention provides chimeric and humanized versions of anti-CD22 mouse monoclonal antibody, HB22.7. The anti-CD22 antibodies of the invention comprise four human or humanized framework regions of the immunoglobulin heavy chain variable region ('VH') and four human or humanized framework r ...


6
Jones Tarran, Williams David G: Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease. Aeres Biomedical, Jones Tarran, Williams David G, CORUZZI Laura A, September 13, 2007: WO/2007/103469 (9 worldwide citation)

The present invention provides chimeric and humanized versions of anti-CD22 mouse monoclonal antibody, HB22.7. The anti-CD22 antibodies of the invention comprise four human or humanized framework regions of the immunoglobulin heavy chain variable region ('VH') and four human or humanized framework r ...


7
JONES TARRAN, WILLIAMS DAVID G: Anticorps humanisés anti CD22 et leur utilisation dans le traitement de loncologie, la transplantation et les maladies auto-immunes, Humanisierte Anti-CD22-Antikörper und ihre Verwendung bei der Behandlung von Krebs, Transplantationen und Autoimmunerkrankungen, Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease. AERES BIOMEDICAL, January 2, 2013: EP2540741-A1

The present application provides chimeric and humanized versions of anti-CD22 mouse monoclonal antibody, HB22.7. The anti-CD22 antibodies of the invention comprise four human or humanized framework regions of the immunoglobulin heavy chain variable region ('VH') and four human or humanized framework ...


8
JONES TARRAN, WILLIAMS DAVID G: [fr] Anticorps humanisés anti CD22 et leur utilisation dans le traitement de loncologie, la transplantation et les maladies auto-immunes, [de] Humanisierte Anti-CD22-Antikörper und ihre Verwendung bei der Behandlung von Krebs, Transplantationen und Autoimmunerkrankungen, [en] Humanized Anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease. AERES BIOMEDICAL, October 16, 2013: EP2650306-A1

[en] The present invention provides chimeric and humanized versions of anti-CD22 mouse monoclonal antibody, HB22.7. The anti-CD22 antibodies of the invention comprise four human or humanized framework regions of the immunoglobulin heavy chain variable region ('VH') and four human or humanized framew ...


9
Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease. January 31, 2013: US20130028888-A1

The present invention provides chimeric and humanized versions of anti-CD22 mouse monoclonal antibody, HB22.7. The anti-CD22 antibodies of the invention comprise four human or humanized framework regions of the immunoglobulin heavy chain variable region (“VH”) and four human or humanized framework r ...


10